Klin Farmakol Farm. 2016;30(1):5-10 | DOI: 10.36290/far.2016.002
Purpose: Solidago virgaurea „goldenrod“ is a known medicinal plant that has been used since ancient times (1, 2). The genus Solidago
is interesting in terms of both biological effects and the presence of many interesting secondary metabolites – flavonoids,
phenolic acids and glucosides, polysaccharides and others (3). Solidago virgaurea is known to exhibit diuretic, antiinflammatory
and newly described antitumoral, antimicrobial, sedative and hypotensive effects (1, 2). Primarily flavonoids and phenolic diglucoside
– leiocarposide belong to secondary metabolites having primarily a positive effect on diuresis (3). Our objective was to
investigate whether Solidaginis virgaureae herba extract, decoction and leachate affect the properties of phase I biotransformation
enzymes, namely cytochromes P450 in human liver microsomal fraction and also in primary cultures of human hepatocytes.
Methods: Different concentrations of Solidaginis virgaureae herba extract, decoction and leachate, expressed as mg of dry weight
in mL of water (0.042 mg/mL; 0.083 mg/mL and 0.167 mg/mL) were studied. Enzyme activities and protein expression were determined
using HPLC and Western blotting, respectively.
Results: Activity and protein expression of CYP1A2, CYP2A6, CYP2C9, CYP2D6 and CYP3A4 were only little influenced by Solidaginis
virgaureae herba preparations, either in human hepatocytes as well as in human liver microsomal fraction in all studied
concentrations.
Conclusion: Based on the results of the enzyme activities and the amount of protein can be expected that the Solidaginis virgaureae
herba preparations do not significantly affect the metabolism of concomitantly administered drugs and their use probably
does not result in drug interactions.
Published: May 30, 2016 Show citation
ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |